Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: William Ericson, David Botstein, Gavin Wood, Nicolas Cartier

Premium

Pacific Biosciences' shareholders have re-elected William Ericson and David Botstein to continue serving as members of its board of directors.

Botstein is director of the Lewis-Sigler Institute for Integrative Genomics and a professor at Princeton University, and he formerly was VP for science at Genentech. Ericson is a general partner at Mohr Davidow Ventures.


Affymetrix has named Gavin Wood as its new chief financial officer. He will replace outgoing CFO Tim Barabe, who is set to leave the company on June 28.

Wood has worked for Affymetrix for seven years. He will be relocating to California from the UK to take over as CFO. He most recently served as vice president of finance, international controller, where he was responsible for Europe and Asia Pacific. Wood is a chartered accountant and prior to joining Affymetrix, he held positions at Unipart and Grant Thornton LLP.


BioMérieux has appointed Nicolas Cartier to be corporate VP of its Industrial Microbiology Unit. He also will become a member of the company's management committee. Cartier has been general manager of Sanofi France since 2009, and he held a number of other posts with Sanofi in its Southeast Asia, China, and Mexico City operations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.